Positron emission tomography of a human prostate cancer xenograft

Association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal

David B. Agus, David W. Golde, George Sgouros, Ase Ballangrud, Carlos Cordon-Cardo, Howard I. Scher

Research output: Contribution to journalArticle

Abstract

The current means of assessing response in prostate cancer are imprecise because changes in tumor size are often slow and difficult to document, and alterations in serum prostate-specific antigen (PSA) levels do not always correlate with clinical outcomes. Using the CWR22 human prostate cancer xenograft model, serial changes in prostate tumor metabolism were assessed after androgen withdrawal by [3H]deoxyglucose (DOG) accumulation in the tumors and noninvasively using positron emission tomography (PET) with 2- [18F]-fluoro-2-deoxy-D-glucose as a radiotracer. A significant decrease in [3H]DOG accumulation was observed at 48 h after androgen withdrawal [62% of preandrogen withdrawal value (95% confidence interval: 0.59, 0.65)], reaching a maximum decline at day 10 [38 % of preandrogen withdrawal value (95% confidence interval: 0.37, 0.40)]. Using PET, parallel changes in tumor metabolism were demonstrated and preceded changes in tumor volume and marked declines in serum PSA. DOG accumulation returned to near baseline upon reintroduction of androgen. The decrease in DOG accumulation was associated with a decline in the proportion of tumor cells in active cell cycle from >60% to 0/early G1 state. DOG accumulation in tumor cells, measured directly and by PET, correlated with androgen changes in the host. The results suggest that serial monitoring of DOG accumulation using PET scanning may be useful as an early indicator of treatment efficacy and other outcome measures in prostate cancer.

Original languageEnglish (US)
Pages (from-to)3009-3014
Number of pages6
JournalCancer Research
Volume58
Issue number14
StatePublished - Jul 15 1998
Externally publishedYes

Fingerprint

Deoxyglucose
Heterografts
Positron-Emission Tomography
Androgens
Prostatic Neoplasms
Outcome Assessment (Health Care)
Neoplasms
Prostate-Specific Antigen
Confidence Intervals
Fluorodeoxyglucose F18
Tumor Burden
Serum
Prostate
Cell Cycle

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Positron emission tomography of a human prostate cancer xenograft : Association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. / Agus, David B.; Golde, David W.; Sgouros, George; Ballangrud, Ase; Cordon-Cardo, Carlos; Scher, Howard I.

In: Cancer Research, Vol. 58, No. 14, 15.07.1998, p. 3009-3014.

Research output: Contribution to journalArticle

@article{b6b67a558753447aae325b7bfa5f72e7,
title = "Positron emission tomography of a human prostate cancer xenograft: Association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal",
abstract = "The current means of assessing response in prostate cancer are imprecise because changes in tumor size are often slow and difficult to document, and alterations in serum prostate-specific antigen (PSA) levels do not always correlate with clinical outcomes. Using the CWR22 human prostate cancer xenograft model, serial changes in prostate tumor metabolism were assessed after androgen withdrawal by [3H]deoxyglucose (DOG) accumulation in the tumors and noninvasively using positron emission tomography (PET) with 2- [18F]-fluoro-2-deoxy-D-glucose as a radiotracer. A significant decrease in [3H]DOG accumulation was observed at 48 h after androgen withdrawal [62{\%} of preandrogen withdrawal value (95{\%} confidence interval: 0.59, 0.65)], reaching a maximum decline at day 10 [38 {\%} of preandrogen withdrawal value (95{\%} confidence interval: 0.37, 0.40)]. Using PET, parallel changes in tumor metabolism were demonstrated and preceded changes in tumor volume and marked declines in serum PSA. DOG accumulation returned to near baseline upon reintroduction of androgen. The decrease in DOG accumulation was associated with a decline in the proportion of tumor cells in active cell cycle from >60{\%} to 0/early G1 state. DOG accumulation in tumor cells, measured directly and by PET, correlated with androgen changes in the host. The results suggest that serial monitoring of DOG accumulation using PET scanning may be useful as an early indicator of treatment efficacy and other outcome measures in prostate cancer.",
author = "Agus, {David B.} and Golde, {David W.} and George Sgouros and Ase Ballangrud and Carlos Cordon-Cardo and Scher, {Howard I.}",
year = "1998",
month = "7",
day = "15",
language = "English (US)",
volume = "58",
pages = "3009--3014",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Positron emission tomography of a human prostate cancer xenograft

T2 - Association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal

AU - Agus, David B.

AU - Golde, David W.

AU - Sgouros, George

AU - Ballangrud, Ase

AU - Cordon-Cardo, Carlos

AU - Scher, Howard I.

PY - 1998/7/15

Y1 - 1998/7/15

N2 - The current means of assessing response in prostate cancer are imprecise because changes in tumor size are often slow and difficult to document, and alterations in serum prostate-specific antigen (PSA) levels do not always correlate with clinical outcomes. Using the CWR22 human prostate cancer xenograft model, serial changes in prostate tumor metabolism were assessed after androgen withdrawal by [3H]deoxyglucose (DOG) accumulation in the tumors and noninvasively using positron emission tomography (PET) with 2- [18F]-fluoro-2-deoxy-D-glucose as a radiotracer. A significant decrease in [3H]DOG accumulation was observed at 48 h after androgen withdrawal [62% of preandrogen withdrawal value (95% confidence interval: 0.59, 0.65)], reaching a maximum decline at day 10 [38 % of preandrogen withdrawal value (95% confidence interval: 0.37, 0.40)]. Using PET, parallel changes in tumor metabolism were demonstrated and preceded changes in tumor volume and marked declines in serum PSA. DOG accumulation returned to near baseline upon reintroduction of androgen. The decrease in DOG accumulation was associated with a decline in the proportion of tumor cells in active cell cycle from >60% to 0/early G1 state. DOG accumulation in tumor cells, measured directly and by PET, correlated with androgen changes in the host. The results suggest that serial monitoring of DOG accumulation using PET scanning may be useful as an early indicator of treatment efficacy and other outcome measures in prostate cancer.

AB - The current means of assessing response in prostate cancer are imprecise because changes in tumor size are often slow and difficult to document, and alterations in serum prostate-specific antigen (PSA) levels do not always correlate with clinical outcomes. Using the CWR22 human prostate cancer xenograft model, serial changes in prostate tumor metabolism were assessed after androgen withdrawal by [3H]deoxyglucose (DOG) accumulation in the tumors and noninvasively using positron emission tomography (PET) with 2- [18F]-fluoro-2-deoxy-D-glucose as a radiotracer. A significant decrease in [3H]DOG accumulation was observed at 48 h after androgen withdrawal [62% of preandrogen withdrawal value (95% confidence interval: 0.59, 0.65)], reaching a maximum decline at day 10 [38 % of preandrogen withdrawal value (95% confidence interval: 0.37, 0.40)]. Using PET, parallel changes in tumor metabolism were demonstrated and preceded changes in tumor volume and marked declines in serum PSA. DOG accumulation returned to near baseline upon reintroduction of androgen. The decrease in DOG accumulation was associated with a decline in the proportion of tumor cells in active cell cycle from >60% to 0/early G1 state. DOG accumulation in tumor cells, measured directly and by PET, correlated with androgen changes in the host. The results suggest that serial monitoring of DOG accumulation using PET scanning may be useful as an early indicator of treatment efficacy and other outcome measures in prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0032528179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032528179&partnerID=8YFLogxK

M3 - Article

VL - 58

SP - 3009

EP - 3014

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 14

ER -